Updated November 9, 2026 · Based on disclosed M&A transactions, 2018–2026
Is my offer fair?
If a private equity platform, a DSO or a larger competitor has made you an offer, the first question is what multiple of EBITDA it implies and how that compares with what businesses your size have actually sold for. The second is how much of the price you get at closing.
Enter the offer below. We compare it with the median and middle half of disclosed deals of the same size in your industry. We only show a comparison where enough deals have been disclosed to publish one.
Check your offer
Published small-deal medians
These are the industries where enough disclosed deals under $100M of enterprise value reported an EBITDA multiple to publish a median. Size matters: across our data, smaller deals sell at lower multiples than platform-sized ones, and they moved less when interest rates rose.
| Industry | Deal size (EV) | Median EV/EBITDA | Middle half | Deals |
|---|---|---|---|---|
| Ambulatory Surgery Center | $5M–$25M | 8.1x | 5.47x–11.38x | 20 |
| Ambulatory Surgery Center | $25M–$100M | 9.1x | 6.72x–12.3x | 10 |
| Dental Practice | $5M–$25M | 6.95x | 6.5x–8.32x | 10 |
| Durable Medical Equipment | Under $5M | 5.3x | 4.3x–7x | 11 |
| Durable Medical Equipment | $5M–$25M | 5x | 4.65x–5.72x | 12 |
| Electronics | $25M–$100M | 9.12x | 6.73x–18.38x | 10 |
| Home Health | Under $5M | 4.7x | 3.9x–6.25x | 25 |
| Industrial Equipment | $25M–$100M | 8.41x | 6.17x–11.29x | 18 |
| Medical Devices | $25M–$100M | 13x | 10.3x–23.25x | 13 |
| Oil & Gas Services | $25M–$100M | 4.01x | 2.25x–9.11x | 13 |
| Primary Care Practice | Under $5M | 3.6x | 3.4x–4.6x | 11 |
| SaaS | $5M–$25M | 10.72x | 8.24x–17.78x | 14 |
| SaaS | $25M–$100M | 12.8x | 5.74x–19.63x | 10 |
| Specialty Medical Practice | $5M–$25M | 5.9x | 5.1x–8.2x | 15 |
| Wholesale Distribution | $25M–$100M | 6.17x | 4.77x–8.79x | 16 |
Source: disclosed transactions from a licensed M&A database, SEC EDGAR filings and verified press releases, 2018–2026. Full breakdowns are on the benchmarks pages.
The price is only half the offer
Two offers with the same headline number can be worth very different amounts. Check these before comparing them:
- Which EBITDA they used. Buyers price off their own adjusted EBITDA. If they reset your pay to a market salary, remove add-backs you count, or use a different twelve months, the multiple on your numbers can look higher or lower than it is.
- Cash at closing. Rollover equity, earnouts and seller notes are paid later, if at all. Earnouts depend on targets you may no longer control after the sale.
- Debt and working capital. Debt is usually paid off from the price, and a working-capital target can move the amount up or down at closing.
- Your role after the sale. Employment terms, compensation and the length of any non-compete are part of the deal. In practice sales they often decide whether the offer works for you.
- Exclusivity. Once you sign an LOI with an exclusivity period, you can’t take other bids. If you have only one offer, that is the moment to find out whether a second buyer would pay more.
- State notice rules. Several states require healthcare deals to be reported 30 to 180 days before closing. Check your state.
Common questions
How do I know if an offer for my business is fair?
Divide the offer price by your trailing twelve-month EBITDA to get the multiple it implies, then compare that with disclosed deals of a similar size in your industry. Then look past the headline: how much is paid in cash at closing, what is deferred into rollover equity, an earnout or a seller note, and which EBITDA figure the buyer used.
Is the offer price what I actually receive?
Usually not. Most offers are on a cash-free, debt-free basis, so the business’s debt is paid off from the price and any cash stays with you. A working-capital target set in the purchase agreement can raise or lower the price at closing. Transaction fees and taxes come off what you keep.
What is rollover equity?
Part of the price paid as shares in the buyer’s company instead of cash. Private equity platforms and DSOs commonly ask owners to roll part of their proceeds. It can be worth more or less than its stated value when the platform is later sold, and you usually cannot sell it before then.
Should I sign a letter of intent with exclusivity?
An LOI with an exclusivity period stops you talking to other buyers while the first one does diligence. That is normal, but it is the point where your leverage drops, so it is worth testing the market before you sign rather than after.
Get a number for your business
The median is the starting point. The full valuation adjusts for your margins, growth, customer or payer concentration and how much the business depends on you.
Value My Business →This page is general information, not advice on a specific offer.